Jennifer Van

US Patent:

8617877, Dec 31, 2013

Filed:

Nov 3, 2008

Appl. No.:

12/740887

Inventors:

Eduardo Marban - Beverly Hills CA, US
Jennifer E. Van Eyk - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

C12N 5/00
C12Q 1/00

US Classification:

435325, 435 4

Abstract:

The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic use.

US Patent:

20180217162, Aug 2, 2018

Filed:

Feb 22, 2016

Appl. No.:

15/552095

Inventors:

- Baltimore MD, US
Jennifer Eileen Van Eyk - Los Angeles CA, US
Vidya Venkatraman - Los Angeles CA, US

International Classification:

G01N 33/68

Abstract:

The present invention relates to the field of myocardial injury. More specifically, the present invention provides methods and compositions useful in the diagnosis, prognosis and/or assessment of myocardial injury. In a specific embodiment, a method comprises the steps of (a) diagnosing a subject as having myocardial injury based on the statistically significant over expression of one or more markers described herein compared to a baseline value, wherein the markers are measured in a biological sample obtained from the subject; and (b) treating the subject with one or more of an anti-thrombolysis agent, coronary bypass surgery or angioplasty.

US Patent:

20180136232, May 17, 2018

Filed:

Nov 15, 2017

Appl. No.:

15/814200

Inventors:

- Los Angeles CA, US
Jennifer E. VAN EYK - Los Angeles CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

G01N 33/68
G01N 33/564
C12Q 1/34

Abstract:

Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins and/or citrullinated peptides. Also disclosed herein are methods, compositions, and kits for diagnosing and/or treating cardiovascular disease.

US Patent:

20170349908, Dec 7, 2017

Filed:

Apr 27, 2017

Appl. No.:

15/498934

Inventors:

- Thousand Oaks CA, US
Nestor Apuya - Culver City CA, US
Karen Chiang - Houston TX, US
Elena Doukhanina - Newbury Park CA, US
Kenneth Feldmann - Newbury Park CA, US
Boris Jankowski - Newbury Park CA, US
Emilio Margolles-Clark - Miami FL, US
Daniel Mumenthaler - Montrose CA, US
Jack Okamuro - Alexandria VA, US
Joon-Hyun Park - Oak Park CA, US
Amr Saad Ragab - Somerset NJ, US
Joel Cruz Rarang - Granada Hills CA, US
Richard Schneeberger - Carlsbad CA, US
Jennifer E. Van Fleet - San Jose CA, US
Ke Zhang - San Clemente CA, US

International Classification:

C12N 15/82
C07K 14/415

Abstract:

Materials and methods for identifying lignin regulatory region-regulatory protein associations are disclosed. Materials and methods for modulating lignin accumulation are also disclosed. In addition, methods and materials for modulating (e.g., increasing or decreasing) the level of a component (e.g., protein, oil, lignin, carbon, a carotenoid, or a triterpenoid) in plants are disclosed.

US Patent:

20160178643, Jun 23, 2016

Filed:

Jul 17, 2014

Appl. No.:

14/905312

Inventors:

- Baltimore MD, US
Jennifer E. Van Eyk - Los Angeles CA, US
Frederick Korley - Fulton MD, US

International Classification:

G01N 33/68

Abstract:

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.